Amgen Makes Repatha ® (Evolocumab) Available In The US At A 60 Percent Reduced List Price

New Option Will Lower Out-of-Pocket Costs for America's Seniors at Risk for Heart Attacks and Strokes THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it is making Repatha® (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per year. This 60 percent reduction from the medicine's original list price will improve affordability by lowering patient copays, especially for Medicare patients. To view the Multimedia News Release, go to: https://www.multivu.com/players/English/8004559-amgen-repatha-reduced-list-price/. ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news